Research graph
References from Antigen prioritization and selection for vaccine design and development: A comprehensive pipeline. Local targets link to admitted publications; unresolved targets remain external evidence.
Accurate structure prediction of biomolecular interactions with AlphaFold 3
10.1038/s41586-024-07487-w · 2024 · External reference
The biogenesis of the immunopeptidome
10.1016/j.smim.2023.101766 · 2023 · External reference
Novel vaccine technologies in veterinary medicine: a herald to human medicine vaccines
2021 · External reference
Enhancing randomized clinical trials with digital twins
10.1038/s41540-025-00592-0 · 2025 · External reference
Clonal driver neoantigen loss under EGFR TKI and immune selection pressures
10.1038/s41586-025-08586-y · 2025 · External reference
Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity
10.1038/s42256-023-00694-6 · 2023 · External reference
Schistosomiasis chemotherapy, chemoprevention, and vaccines: history, progress, and priorities
10.1002/iid3.70054 · 2024 · External reference
Unraveling brucellosis: advances in pathogenesis, diagnostic strategies, therapeutic innovations, and public health perspectives
2025 · External reference
Vaccine design and development: exploring the interface with computational biology and AI
10.1080/08830185.2024.2374546 · 2024 · External reference
Vaccine strategies against latent tuberculosis infection
10.1016/j.tim.2006.11.008 · 2007 · External reference
Computational tools and data integration to accelerate vaccine development: challenges, opportunities, and future directions
10.3389/fimmu.2025.1502484 · 2025 · External reference
Antigen-specific tolerance induction and the immunotherapy of experimental autoimmune disease
1998 · External reference
Fighting persistence: how chronic infections with Mycobacterium tuberculosis evade T cell-mediated clearance and new strategies to defeat them
10.1128/iai.00916-19 · 2020 · External reference
Phosphopeptide neoantigens as emerging targets in cancer immunotherapy
10.33696/cancerimmunol.6.094 · 2024 · External reference
Immunopeptidomics for autoimmunity: unlocking the chamber of immune secrets
10.1038/s41540-024-00482-x · 2025 · External reference
The current landscape of therapeutic vaccination approaches for treatment of HPV-dependent malignancies
10.1038/s41541-026-01426-8 · 2026 · External reference
Accurate prediction of protein structures and interactions using a three-track neural network
10.1126/science.abj8754 · 2021 · External reference
Systemic vaccination induces CD8(+) T cells and remodels the tumor microenvironment
10.1016/j.cell.2022.10.006 · 2022 · External reference
Tracking Cancer evolution through the disease course
10.1158/2159-8290.cd-20-1559 · 2021 · External reference
Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope
10.1038/s41467-018-03632-y · 2018 · External reference
The importance of being presented: target validation by Immunopeptidomics for epitope-specific immunotherapies
10.3389/fimmu.2022.883989 · 2022 · External reference
Rational selection of antigenic targets for group A Streptococcus vaccine: updates, challenges and opportunities
10.1038/s41541-026-01445-5 · 2026 · External reference
Indirect T-cell allorecognition: perspectives for peptide-based therapy in transplantation
10.1016/s0167-5699(97)01004-9 · 1997 · External reference
Proinsulin C-peptide is a major source of HLA-DQ8 restricted hybrid insulin peptides recognized by human islet-infiltrating CD4+ T cells
10.1093/pnasnexus/pgae491 · 2024 · External reference
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand
10.1038/80516 · 2000 · External reference
Discovery of U2AF1 neoantigens in myeloid neoplasms
10.1136/jitc-2023-007490 · 2023 · External reference
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
10.1038/s41571-020-00460-2 · 2021 · External reference
Cancer Neoantigens: challenges and future directions for prediction, prioritization, and validation
10.3389/fonc.2022.836821 · 2022 · External reference
Echinococcus granulosus sensu lato control measures: a specific focus on vaccines for both definitive and intermediate hosts
10.1186/s13071-024-06581-2 · 2024 · External reference
Understanding fc function for rational vaccine design against pathogens
10.1128/mbio.03036-23 · 2024 · External reference
Introduction to Markov state modeling of conformational dynamics
10.1021/acs.jctc.6c00351 · 2026 · External reference
Application of modeling approaches to explore vaccine adjuvant mode-of-action
10.3389/fimmu.2019.02150 · 2019 · External reference
Antigen-specific immunotherapies for autoimmune disease
10.1038/s41584-024-01201-w · 2025 · External reference
Principles and practical applications of structure-based vaccine design
10.1016/j.coi.2022.102209 · 2022 · External reference
Properties of MHC class I presented peptides that enhance immunogenicity
10.1371/journal.pcbi.1003266 · 2013 · External reference
HPV vaccines - A game changer for preventing HPV-related cancers
10.1016/j.ijmmb.2025.100847 · 2025 · External reference
On peptides and altered peptide ligands: from origin, mode of action and design to clinical application (immunotherapy)
10.1159/000448756 · 2016 · External reference
Broad-spectrum vaccines against various and evolving viruses: from antigen design to nanoparticle delivery
10.1128/jvi.00997-25 · 2025 · External reference
Sources of cancer neoantigens beyond single-nucleotide variants
10.3390/ijms231710131 · 2022 · External reference
Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: results from a phase II, randomised, multicentre study
10.1016/j.vaccine.2018.07.023 · 2019 · External reference
Pathways of antigen recognition by T cells in allograft rejection
10.1097/tp.0000000000004420 · 2023 · External reference
Computational methods to predict conformational B-cell epitopes
10.3390/biom14080983 · 2024 · External reference
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
10.1038/s41586-023-06496-5 · 2023 · External reference
Prototype pathogen approach for vaccine and monoclonal antibody development: a critical component of the NIAID plan for pandemic preparedness
10.1093/infdis/jiac296 · 2023 · External reference
Real-time manipulation of T cell-dendritic cell interactions in vivo reveals the importance of prolonged contacts for CD4+ T cell activation
10.1016/j.immuni.2007.08.018 · 2007 · External reference
Design and production of hybrid antigens for targeting integral outer membrane proteins in gram-negative Bacteria
10.1007/978-1-0716-1900-1_8 · 2022 · External reference
A high-throughput immunopeptidome platform for MHC II alleles to characterize antigen-specific CD4+ T cells
10.1016/j.bmt.2025.100112 · 2025 · External reference
Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens
10.1186/s12929-024-01082-x · 2024 · External reference
Principles and therapeutic applications of adaptive immunity
10.1016/j.cell.2024.03.037 · 2024 · External reference
10.1038/s12276-026-01807-y · 2026 · Admitted local publication
Identification of tumor antigens with immunopeptidomics
10.1038/s41587-021-01038-8 · 2022 · External reference
Positive-unlabeled learning identifies vaccine candidate antigens in the malaria parasite plasmodium falciparum
10.1038/s41540-024-00365-1 · 2024 · External reference
Recent development of ruminant vaccine against viral diseases
2021 · External reference
Critical review of conformational B-cell epitope prediction methods
10.1093/bib/bbac567 · 2023 · External reference
Inferring structural variant cancer cell fraction
10.1038/s41467-020-14351-8 · 2020 · External reference
Pathogen evolution and the immunological niche
10.1111/nyas.12493 · 2014 · External reference
Proof of principle for epitope-focused vaccine design
10.1038/nature12966 · 2014 · External reference
Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells
10.1016/j.jbiotec.2012.06.038 · 2012 · External reference
Molecular mimicry, autoimmunity, and infection: the Cross-reactive antigens of group A streptococci and their sequelae
10.1128/microbiolspec.gpp3-0045-2018 · 2019 · External reference
HIV-1 envelope subregion length variation during disease progression
10.1371/journal.ppat.1001228 · 2010 · External reference
A lean reverse vaccinology pipeline with publicly available bioinformatic tools
10.1007/978-1-0716-3239-0_24 · 2023 · External reference
Robust deep learning-based protein sequence design using ProteinMPNN
10.1126/science.add2187 · 2022 · External reference
Brucellae as resilient intracellular pathogens: epidemiology, host-pathogen interaction, recent genomics and proteomics approaches, and future perspectives
10.3389/fvets.2023.1255239 · 2023 · External reference
Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer
2024 · External reference
Cancer cell metabolism and antitumour immunity
10.1038/s41577-024-01026-4 · 2024 · External reference
Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO precision medicine working group
10.1016/j.annonc.2020.05.008 · 2020 · External reference
Analysis of selection in protein-coding sequences accounting for common biases
10.1093/bib/bbaa431 · 2021 · External reference
Glycosylation of therapeutic proteins: a critical quality attribute
10.1007/978-1-0716-1241-5_1 · 2021 · External reference
Single-molecule imaging prefusion intermediate conformations of MERS-CoV spike trimers in membrane during entry
10.1016/j.celrep.2025.115916 · 2025 · External reference
EAACI molecular allergology user’s guide 2.0
2023 · External reference
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy
10.1038/s41467-020-14568-7 · 2020 · External reference
Machine learning for the prediction of size and encapsulation efficiency of mRNA-loaded lipid nanoparticles following a Postencapsulation approach
10.1021/acsabm.5c01883 · 2026 · External reference
Current approaches to malaria vaccines
10.1016/j.mib.2022.102227 · 2022 · External reference
Allergen immunotherapy: past, present and future
10.1038/s41577-022-00786-1 · 2023 · External reference
Urinary bladder Schistosoma haematobium-related squamous cell carcinoma: a report of two fatal cases and literature review
10.1186/s40794-022-00161-x · 2022 · External reference
Artificial intelligence-, organoid-, and organ-on-chip-powered models to improve pre-clinical animal testing of vaccines and immunotherapeutics: potential, progress, and challenges
10.3389/frai.2025.1681106 · 2025 · External reference
Novelty search promotes antigenic diversity in microbial pathogens
10.3390/pathogens12030388 · 2023 · External reference
Host-pathogen interactions influencing zoonotic spillover potential and transmission in humans
10.3390/v15030599 · 2023 · External reference
Assessing developability early in the discovery process for novel biologics
10.1080/19420862.2023.2171248 · 2023 · External reference
A “hit-and-run” affair - A possible link for cancer progression in virally driven cancers
10.1016/j.bbcan.2020.188476 · 2021 · External reference
A systematic safety pipeline for selection of T-cell receptors to enter clinical use
10.1038/s41541-023-00713-y · 2023 · External reference
CNS infection and immune privilege
10.1038/s41583-018-0070-8 · 2018 · External reference
Giving CD4+ T cells the slip: viral interference with MHC class II-restricted antigen processing and presentation
10.1016/j.coi.2016.03.003 · 2016 · External reference
Early engineering approaches to improve peptide developability and manufacturability
10.1208/s12248-014-9681-9 · 2015 · External reference
Neoantigen cancer vaccines in the mRNA era: antigen selection, platform engineering, and clinical translation
2026 · External reference
Lessons from a decade of adult vaccine rollout in low- and middle-income countries: a scoping review
10.1080/14760584.2024.2375329 · 2024 · External reference
Generation of a virus-like particles based vaccine against IgE
10.1111/all.16090 · 2024 · External reference
Vaccine-induced anti-IgE antibodies neutralize free IgE but fail to bind and activate mast cell-displayed IgE
10.1111/all.16530 · 2025 · External reference
Deciphering tumour heterogeneity: from tissue to liquid biopsy
10.3390/cancers14061384 · 2022 · External reference
Correlates of protection against SARS-CoV-2 infection and COVID-19 disease
10.1111/imr.13091 · 2022 · External reference
Small extracellular vesicles in transplant rejection
10.3390/cells10112989 · 2021 · External reference
Spatial oncology: translating contextual biology to the clinic
10.1016/j.ccell.2024.09.001 · 2024 · External reference
A guide to current methodology and usage of reverse vaccinology towards in silico vaccine discovery
10.1093/femsre/fuad004 · 2023 · External reference
TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo
10.1084/jem.20091999 · 2010 · External reference
Vaccines for cancer prevention: exploring opportunities and navigating challenges
10.1038/s41573-024-01081-5 · 2025 · External reference
Structure-based vaccine antigen design
10.1146/annurev-med-121217-094234 · 2019 · External reference
Recent developments in vaccine design: from live vaccines to recombinant toxin vaccines
10.3390/toxins15090563 · 2023 · External reference
Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types
10.1038/s41587-023-01945-y · 2024 · External reference
Identification and relative abundance of naturally presented and cross-reactive influenza A virus MHC class I-restricted T cell epitopes
10.1080/22221751.2024.2306959 · 2024 · External reference
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
10.1038/s41568-024-00761-z · 2025 · External reference
MHC class I antigen presentation: learning from viral evasion strategies
10.1038/nri2575 · 2009 · External reference
Development and clinical applications of therapeutic Cancer vaccines with individualized and shared Neoantigens
2024 · External reference
SARS-CoV-2 variants, spike mutations and immune escape
10.1038/s41579-021-00573-0 · 2021 · External reference
Hybrid insulin peptides as antigens and Tolerogens for pathogenic T cells in autoimmune diabetes
10.1111/imr.70142 · 2026 · External reference
Memory CD8+ T cell-mediated protection against liver-stage malaria
10.1111/imr.13202 · 2023 · External reference
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
10.1038/s41577-022-00753-w · 2023 · External reference
The effector function of allergens
10.3389/falgy.2022.818732 · 2022 · External reference
Limits on inferring T cell specificity from partial information
10.1073/pnas.2408696121 · 2024 · External reference
Recent advances in our understanding of the allograft response
10.12703/r/10-21 · 2021 · External reference
A novel pathway of alloantigen presentation by dendritic cells
10.4049/jimmunol.173.8.4828 · 2004 · External reference
Proactive vaccination using multiviral quartet Nanocages to elicit broad anti-coronavirus responses
10.1038/s41565-024-01655-9 · 2024 · External reference
Regulatory void for vaccines targeting eukaryotic parasites of farmed and domestic animals and fish
10.3389/fpara.2022.1073801 · 2022 · External reference
Turning the corner on therapeutic cancer vaccines
10.1038/s41541-019-0103-y · 2019 · External reference
Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection
10.1161/01.cir.101.20.2405 · 2000 · External reference
Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells
10.1038/cmi.2015.112 · 2016 · External reference
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
10.1126/science.abd0826 · 2020 · External reference
Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases
10.1038/s41588-020-0628-z · 2020 · External reference
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
10.1038/s41591-020-01206-4 · 2021 · External reference
Host range and structural analysis of bat-origin RshSTT182/200 coronavirus binding to human ACE2 and its animal orthologs
10.15252/embj.2022111737 · 2023 · External reference
The neoantigens derived from transposable elements - A hidden treasure for cancer immunotherapy
10.1016/j.bbcan.2024.189126 · 2024 · External reference
Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2
10.1038/s41467-023-35949-8 · 2023 · External reference
Highly scalable prefusion-stabilized RSV F vaccine with enhanced immunogenicity and robust protection
10.1038/s41467-025-63084-z · 2025 · External reference
Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development
10.1038/s41577-025-01208-8 · 2026 · External reference
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy
10.1038/s41587-024-02420-y · 2025 · External reference
Immune self-reactivity triggered by drug-modified HLA-peptide repertoire
10.1038/nature11147 · 2012 · External reference
Evaluating the impact of N-glycan Sequon removal in the p27 peptide on RSV F protein immunogenicity and functionality
10.3390/v16121848 · 2024 · External reference
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
10.1038/s41568-021-00339-z · 2021 · External reference
Highly accurate protein structure prediction with AlphaFold
10.1038/s41586-021-03819-2 · 2021 · External reference
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The altered peptide ligand in relapsing MS study group
10.1038/80525 · 2000 · External reference
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
10.1093/nar/gkr695 · 2011 · External reference
Challenges in developing personalized neoantigen cancer vaccines
10.1038/s41577-023-00937-y · 2024 · External reference
Challenges in developing personalized neoantigen cancer vaccines
10.1038/s41577-023-00937-y · 2024 · External reference
The ABC of major histocompatibility complexes and T cell receptors in health and disease
10.1089/vim.2019.0184 · 2020 · External reference
TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study
10.1053/j.gastro.2021.03.014 · 2021 · External reference
Therapeutic induction of antigen-specific immune tolerance
10.1038/s41577-023-00970-x · 2024 · External reference
Why does drug resistance readily evolve but vaccine resistance does not?
2017 · External reference
Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease
2003 · External reference
Fast-tracking vaccine manufacturing: CEPI’S rapid response framework for the 100 days Mission
2025 · External reference
Allergenic characteristics of a modified peanut allergen
10.1002/mnfr.200500073 · 2005 · External reference
CEPI workshop report: applying disease X vaccine library and Knowledge Base approaches to severe fever with thrombocytopenia syndrome (SFTS)
2026 · External reference
Requirements for effective IgE cross-linking on mast cells and basophils
10.1002/mnfr.200500272 · 2006 · External reference
Targeting latent viral infection in EBV-associated lymphomas
10.3389/fimmu.2024.1342455 · 2024 · External reference
Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions
10.1016/j.isci.2022.103850 · 2022 · External reference
Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes
10.1038/nm.4289 · 2017 · External reference
All the small things: how virus-like particles and liposomes modulate allergic immune responses
10.1002/eji.201847810 · 2020 · External reference
Capacity building for vaccine manufacturing across developing countries: the way forward
10.1080/21645515.2021.2020529 · 2022 · External reference
Targeting FoxO proteins induces lytic reactivation of KSHV for treating herpesviral primary effusion lymphoma
10.1371/journal.ppat.1011581 · 2023 · External reference
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM
10.1038/s41586-022-04432-7 · 2022 · External reference
Mucosal vaccines — fortifying the frontiers
10.1038/s41577-021-00583-2 · 2022 · External reference
Protein language models: applications and perspectives
10.1021/acs.jproteome.5c00506 · 2026 · External reference
Targeting infection-specific peptides in immunopeptidomics studies for vaccine target discovery
10.1084/jem.20250444 · 2025 · External reference
Viral infection, APOBEC3 dysregulation, and cancer
10.3389/fgene.2024.1489324 · 2024 · External reference
Scientific approaches to defining HPV vaccine-induced protective immunity
10.1002/ijc.35345 · 2025 · External reference
CD4(+) T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors
10.1038/s41423-024-01133-1 · 2024 · External reference
Virus infections and cancers: from mechanisms to therapeutics
10.1186/s43556-026-00485-6 · 2026 · External reference
Evolutionary-scale prediction of atomic-level protein structure with a language model
10.1126/science.ade2574 · 2023 · External reference
A systematic review of the impact of vaccine reactogenicity on willingness to accept influenza vaccination in adults
10.1016/j.vaccine.2026.128195 · 2026 · External reference
Contribution of direct and indirect recognition pathways to T cell alloreactivity
10.1084/jem.177.6.1643 · 1993 · External reference
Computationally optimized SARS-CoV-2 MHC class I and II vaccine formulations predicted to target human haplotype distributions
10.1016/j.cels.2020.06.009 · 2020 · External reference
Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2
10.1073/pnas.2025373118 · 2021 · External reference
In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastoma
10.1186/s13059-024-03404-6 · 2024 · External reference
Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
10.1136/jitc-2021-003001 · 2021 · External reference
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities
10.1038/s41698-024-00665-z · 2024 · External reference
Beyond binding: antibody effector functions in infectious diseases
10.1038/nri.2017.106 · 2018 · External reference
Potential therapeutic targets for the treatment of HPV-associated malignancies
10.3390/cancers16203474 · 2024 · External reference
Mechanisms of autoantibody-induced pathology
2017 · External reference
T cell adaptation in chronic infections and tumors
10.1038/s41423-026-01405-y · 2026 · External reference
Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2
10.1038/s41564-023-01359-1 · 2023 · External reference
Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists
10.1126/science.7824949 · 1995 · External reference
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy
10.1016/j.trecan.2021.07.006 · 2021 · External reference
Molecular mimicry as a mechanism of viral immune evasion and autoimmunity
10.1038/s41467-024-53658-8 · 2024 · External reference
Guards and decoys: RIPoptosome and inflammasome pathway regulators of bacterial effector-triggered immunity
10.1371/journal.ppat.1012884 · 2025 · External reference
Synthetic peptides with inadvertent chemical modifications can activate potentially autoreactive T cells
10.4049/jimmunol.2000756 · 2021 · External reference
Mapping intratumor heterogeneity across layers for advancing immunotherapy
10.1016/j.cell.2026.03.025 · 2026 · External reference
Epitope-specific antibodies in allergic disease and clinical tolerance
10.1111/imr.70042 · 2025 · External reference
Allorecognition by T lymphocytes and allograft rejection
10.3389/fimmu.2016.00582 · 2016 · External reference
Genetic immune escape landscape in primary and metastatic cancer
10.1038/s41588-023-01367-1 · 2023 · External reference
Aberrant glycosylation as immune therapeutic targets for solid tumors
10.3390/cancers15143536 · 2023 · External reference
Immunopeptidomics for next-generation bacterial vaccine development
10.1016/j.tim.2021.04.010 · 2021 · External reference
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
10.1126/science.aaf1490 · 2016 · External reference
Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus
10.1126/science.1243283 · 2013 · External reference
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody
10.1126/science.1234914 · 2013 · External reference
Immunization of cattle with a combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge
10.1016/j.vaccine.2009.10.076 · 2010 · External reference
How chemokines organize the tumour microenvironment
10.1038/s41568-023-00635-w · 2024 · External reference
Applied immunoinformatics in modern vaccine design: a comprehensive review of available computational tools
10.1016/j.vaccine.2026.128392 · 2026 · External reference
HPV integration and cervical cancer: a failed evolutionary viral trait
10.1016/j.molmed.2024.05.009 · 2024 · External reference
Vaccines against diseases transmitted from animals to humans: a one health paradigm
10.1016/j.vaccine.2013.09.029 · 2013 · External reference
The central role of HLA class II-restricted helper Neoantigen vaccines in cancer immunotherapy
10.3390/cancers18152461 · 2026 · External reference
Beyond antigens and adjuvants: formulating future vaccines
10.1172/jci81083 · 2016 · External reference
Helicobacter pylori-induced DNA double-stranded break in the development of gastric cancer
10.1111/cas.15357 · 2022 · External reference
The role of the large T antigen in the molecular pathogenesis of Merkel cell carcinoma
10.3390/genes15091127 · 2024 · External reference
An adjuvant database for preclinical evaluation of vaccines and immunotherapeutics. Cell
2025 · External reference
Targeting the pMHC-TCR interaction: molecular strategies and therapeutic potential in autoimmunity
10.3390/ijms27083622 · 2026 · External reference
Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens
10.1016/j.biotechadv.2023.108283 · 2024 · External reference
MHCflurry 2.0: improved Pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing
10.1016/j.cels.2020.06.010 · 2020 · External reference
Molecular mimicry and immune-mediated diseases
10.1096/fasebj.12.13.1255 · 1998 · External reference
T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues
10.4049/jimmunol.150.10.4277 · 1993 · External reference
The promises and challenges of neoantigen cancer vaccines
10.1038/s41587-026-03018-2 · 2026 · External reference
An immunogenic personal neoantigen vaccine for patients with melanoma
10.1038/nature22991 · 2017 · External reference
Glycosylation as a key parameter in the design of nucleic acid vaccines
10.1016/j.sbi.2022.102348 · 2022 · External reference
A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization
10.1016/j.ccell.2023.12.016 · 2024 · External reference
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
10.1073/pnas.1707304114 · 2017 · External reference
Epigenetic regulation of tumor immunity
10.1172/jci178540 · 2024 · External reference
Reshaping tumor immune microenvironment by Epstein-Barr virus activation in the stroma of colorectal cancer
10.1016/j.isci.2022.105919 · 2023 · External reference
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group
10.1016/j.annonc.2022.05.520 · 2022 · External reference
Sustainable development goal halftime project: benefit-cost analysis using methods from the decade of vaccine economics model
10.1017/bca.2023.11 · 2023 · External reference
Spillover: mechanisms, genetic barriers, and the role of reservoirs in emerging pathogens
10.3390/microorganisms12112191 · 2024 · External reference
Targeting public neoantigens for cancer immunotherapy
2021 · External reference
The landscape of T cell antigens for cancer immunotherapy
2023 · External reference
Virus-like particles and nanoparticles for vaccine development against HCMV
10.3390/v12010035 · 2019 · External reference
T cell epitope predictions
10.1146/annurev-immunol-082119-124838 · 2020 · External reference
A guide to antigen processing and presentation
10.1038/s41577-022-00707-2 · 2022 · External reference
Nomenclature for immune correlates of protection after vaccination
10.1093/cid/cis238 · 2012 · External reference
The complexity and cost of vaccine manufacturing - An overview
10.1016/j.vaccine.2017.06.003 · 2017 · External reference
A guide to vaccinology: from basic principles to new developments
10.1038/s41577-020-00479-7 · 2021 · External reference
T-cell activation-induced marker assays in health and disease
10.1111/imcb.12636 · 2023 · External reference
Mycobacterium tuberculosis bacteriology and immunity necessitate a multi-pronged immune strategy for vaccination
10.1038/s41541-026-01387-y · 2026 · External reference
Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins
10.1016/j.vaccine.2003.08.007 · 2004 · External reference
Targeting tumor heterogeneity with neoantigen-based cancer vaccines
10.1158/0008-5472.can-23-2042 · 2024 · External reference
The role of bioinformatics algorithms in modern biopharmaceutical design: progress, challenges, and future perspectives
10.34172/bi.33072 · 2025 · External reference
What can ribo-seq, immunopeptidomics, and proteomics tell us about the noncanonical proteome?
10.1016/j.mcpro.2023.100631 · 2023 · External reference
MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution
10.1038/s41588-024-01883-8 · 2024 · External reference
Disease X vaccine production and supply chains: risk assessing healthcare systems operating with artificial intelligence and industry 4.0
10.1007/s12553-022-00722-2 · 2023 · External reference
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
10.1038/s41591-024-02851-9 · 2024 · External reference
Reverse vaccinology 2.0: human immunology instructs vaccine antigen design
10.1084/jem.20151960 · 2016 · External reference
Facilitators and barriers to vaccination uptake in pregnancy: a qualitative systematic review
10.1371/journal.pone.0298407 · 2024 · External reference
Helicobacter pylori and its role in gastric Cancer
10.3390/microorganisms11051312 · 2023 · External reference
NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data
10.1093/nar/gkaa379 · 2020 · External reference
Best practices for bioinformatic characterization of neoantigens for clinical utility
10.1186/s13073-019-0666-2 · 2019 · External reference
T cell Cross-reactivity between a highly immunogenic EBV epitope and a self-peptide naturally presented by HLA-B*18:01+ cells
10.4049/jimmunol.1500233 · 2015 · External reference
Cancer immune evasion, immunoediting and intratumour heterogeneity
10.1038/s41577-024-01111-8 · 2025 · External reference
Allorecognition
10.1034/j.1600-6143.2001.10201.x · 2001 · External reference
Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC
10.1038/s41586-025-10004-2 · 2026 · External reference
StealTHY: an immunogen-free CRISPR platform to expose concealed metastasis regulators in immunocompetent models
10.1016/j.cell.2025.10.007 · 2025 · External reference
Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies
10.1038/s41541-022-00470-4 · 2022 · External reference
Antibody reactivity against EBNA1 and GlialCAM differentiates multiple sclerosis patients from healthy controls
10.1073/pnas.2424986122 · 2025 · External reference
Cancer mRNA vaccines: clinical advances and future opportunities
10.1038/s41571-024-00902-1 · 2024 · External reference
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors
10.1038/s41467-023-38946-z · 2023 · External reference
Antigenic variability: obstacles on the road to vaccines against traditionally difficult targets
10.1080/21645515.2016.1191718 · 2016 · External reference
RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer
10.1038/s41586-024-08508-4 · 2025 · External reference
Integrative spatial and genomic analysis of tumor heterogeneity with Tumoroscope
10.1038/s41467-024-53374-3 · 2024 · External reference
Predicting genetic evolution of viruses to identify suitable vaccines using artificial intelligence
10.1038/s41598-026-35143-y · 2026 · External reference
Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI position paper
10.1111/all.13138 · 2017 · External reference
Comprehensive self-antigen screening to assess cross-reactivity in promiscuous T-cell receptors
10.3389/fimmu.2025.1719827 · 2026 · External reference
Ionic liquid-based strategy for predicting protein aggregation propensity and thermodynamic stability
10.1021/jacsau.2c00356 · 2022 · External reference
Beyond sequence: posttranslational remodeling of antigens in autoimmunity
10.1111/imr.70150 · 2026 · External reference
Sarbecovirus RBD indels and specific residues dictating multi-species ACE2 adaptiveness
10.1038/s41467-024-53029-3 · 2024 · External reference
Computational epitope map of SARS-CoV-2 spike protein
10.1371/journal.pcbi.1008790 · 2021 · External reference
Production and cryo-electron microscopy structure of an internally tagged SARS-CoV-2 spike ecto-domain construct
2025 · External reference
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
10.1136/jitc-2022-005924 · 2023 · External reference
Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities
10.1016/j.jaut.2006.12.002 · 2006 · External reference
Mechanistic insights into liver-fluke-induced bile-duct cancer
10.1016/j.pt.2024.10.012 · 2024 · External reference
Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines
10.1172/jci176740 · 2024 · External reference
Post-translational modifications in tumor-associated antigens as a platform for novel Immuno-oncology therapies
10.3390/cancers15010138 · 2022 · External reference
An unfolded variant of the major peanut allergen Ara h 2 with decreased anaphylactic potential
10.1111/cea.12031 · 2012 · External reference
Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
10.1016/j.cell.2020.08.012 · 2020 · External reference
Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 omicron BA.1 and BA.2 receptor-binding domains
10.1371/journal.ppat.1010951 · 2022 · External reference
ACE2 binding is an ancestral and evolvable trait of sarbecoviruses
10.1038/s41586-022-04464-z · 2022 · External reference
A potent broad-spectrum neutralizing antibody targeting a conserved region of the prefusion RSV F protein
10.1038/s41467-024-54384-x · 2024 · External reference
T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells
10.1111/cei.12570 · 2015 · External reference
M2e-based influenza vaccines with nucleoprotein: a review
2021 · External reference
Aberrant B cell responses as drivers of autoantibody generation and epitope diversification in SLE pathogenesis
2026 · External reference
Learning from prepandemic data to forecast viral escape
10.1038/s41586-023-06617-0 · 2023 · External reference
Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets
10.1007/s00430-019-00649-y · 2020 · External reference
T cell receptor recognition of hybrid insulin peptides bound to HLA-DQ8
10.1038/s41467-021-25404-x · 2021 · External reference
Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses
10.1038/s41551-023-01086-2 · 2023 · External reference
Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity
10.1016/j.jaci.2019.08.036 · 2020 · External reference
HBV-induced carcinogenesis: mechanisms, correlation with viral suppression, and implications for treatment
10.1111/liv.16202 · 2025 · External reference
The role of the polymeric immunoglobulin receptor and secretory immunoglobulins during mucosal infection and immunity
10.3390/v10050237 · 2018 · External reference
Prediction and reduction of the aggregation of monoclonal antibodies
10.1016/j.jmb.2017.03.014 · 2017 · External reference
Dendritic cells guide islet autoimmunity through a restricted and uniquely processed Peptidome presented by high-risk HLA-DR
10.4049/jimmunol.1501282 · 2016 · External reference
Epitope spreading in immune-mediated diseases: implications for immunotherapy
10.1038/nri724 · 2002 · External reference
Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction
10.1097/00007890-199709270-00001 · 1997 · External reference
Toward rational vaccine engineering
10.1016/j.addr.2022.114142 · 2022 · External reference
Pathogenesis of allergic diseases and implications for therapeutic interventions
10.1038/s41392-023-01344-4 · 2023 · External reference
Immune correlates of protection as a game changer in tuberculosis vaccine development
10.1038/s41541-024-01004-w · 2024 · External reference
Artificial intelligence for precision oncology from phenotyping and drug discovery to clinical translation
2026 · External reference
De novo design of protein structure and function with RFdiffusion
10.1038/s41586-023-06415-8 · 2023 · External reference
Glycan positioning impacts HIV-1 Env glycan-shield density, function, and recognition by antibodies
10.1016/j.isci.2020.101711 · 2020 · External reference
The immune microenvironment of pathogen-associated cancers and current clinical therapeutics
10.1186/s12943-025-02448-x · 2025 · External reference
Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells
10.1073/pnas.152345899 · 2002 · External reference
How CEPI can enhance global vaccine equity and transparency
10.1016/s0140-6736(26)01137-2 · 2026 · External reference
Adaptive immune activation: glycosylation does matter
10.1038/nchembio.1403 · 2013 · External reference
Antigen presentation in vertebrates: structural and functional aspects
10.1016/j.dci.2023.104702 · 2023 · External reference
Mini-review on the therapeutic vaccines targeting chronic infectious diseases: evaluation system of therapeutic vaccines targeting HPV and EBV-related cancers
10.1080/21645515.2025.2457187 · 2025 · External reference
Unresolved reference
2026 · External reference
Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers
10.1038/s41467-024-48031-8 · 2024 · External reference
Personalized neoantigen cancer vaccines: current progression, challenges and a bright future
10.1007/s10238-024-01436-7 · 2024 · External reference
Design of intrinsically disordered region binding proteins
10.1126/science.adr8063 · 2025 · External reference
Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors
10.1038/s41467-023-40850-5 · 2023 · External reference
Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application
10.1097/cm9.0000000000003708 · 2025 · External reference
Diverse roles of antibodies in antibody-drug conjugates
10.3390/ph18020180 · 2025 · External reference
Structural biology of SARS-CoV-2 and implications for therapeutic development
10.1038/s41579-021-00630-8 · 2021 · External reference
Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer
10.1007/s00011-021-01501-x · 2021 · External reference
Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy
10.1038/s41571-023-00789-4 · 2023 · External reference
Hepatitis B virus DNA integration drives carcinogenesis and provides a new biomarker for HBV-related HCC
10.1016/j.jcmgh.2023.01.001 · 2023 · External reference
Lytic induction therapy against Epstein-Barr virus-associated malignancies: past, present, and future
10.3390/cancers12082142 · 2020 · External reference
Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy
2026 · External reference
Targeting TFH cells in human diseases and vaccination: rationale and practice
10.1038/s41590-022-01253-8 · 2022 · External reference
T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance
10.5415/apallergy.2016.6.2.77 · 2016 · External reference
Advances in Helicobacter pylori vaccine research: from candidate antigens to adjuvants-A review
10.1111/hel.13034 · 2024 · External reference
Recent advances in therapeutic cancer vaccines
10.1038/s41568-025-00820-z · 2025 · External reference
Disulfide bond formation and its impact on the biological activity and stability of recombinant therapeutic proteins produced by Escherichia coli expression system
10.1016/j.biotechadv.2011.07.013 · 2011 · External reference
Single-cell analysis of target antigens of CAR-T reveals a potential landscape of “on-target, off-tumor toxicity”
10.3389/fimmu.2021.799206 · 2021 · External reference
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
10.1038/s41577-022-00813-1 · 2023 · External reference
Identification of indirect CD4(+) T cell epitopes associated with transplant rejection provides a target for donor-specific tolerance induction
10.1016/j.immuni.2025.01.008 · 2025 · External reference
TCF1 in T cell immunity: a broadened frontier
10.1038/s41577-021-00563-6 · 2022 · External reference
Deep-learning-based single-domain and multidomain protein structure prediction with D-I-TASSER
10.1038/s41587-025-02654-4 · 2026 · External reference
Factors that influence the immune response to vaccination
10.1128/cmr.00084-18 · 2019 · External reference
Inverse vaccination for autoimmune diseases: insights into the role of B lymphocytes
10.3390/cells14141085 · 2025 · External reference
